Benefits of continuous subcutaneous insulin infusion in children with type 1 diabetes - 29/08/11
, Jonathan Planton, BS, Leonard Egede, MD, Sharon Schwarz, RN, MSN, CDE
Reprint requests: Steven M. Willi, MD, Associate Professor, Department of Pediatrics, Medical University of South Carolina, 96 Jonathan Lucas St, Clinical Sciences Building, Room 316, Charleston, SC 29425.Abstract |
Objective |
To examine the effect of continuous subcutaneous insulin infusion (CSII) therapy on parameters affecting long-term outcome in type 1 diabetes.
Study design |
Height, weight, body mass index, insulin dose, glycosylated hemoglobin (HbA1C), and blood glucose data from home meter downloads were collected prospectively for analysis in 51 children (age, 10.7±3.1 years, mean±SD) throughout the 12 months before and after introducing CSII.
Results |
Before pump initiation, HbA1C was relatively stable, but it fell to 7.7±0.2% (P<.001) within 3 months of CSII and remained decreased (7.9±0.1%) at 12 months (P<.01). In contrast, weight standard deviation score increased before CSII (from 0.50±0.13 to 0.60±0.13, P<.05), but remained unchanged (0.61±0.11) in the year thereafter. Although severe hypoglycemia (<50 mg/dL) was reduced in the entire cohort, HbA1C improved primarily in young children and teenagers. Comparison of glycemic responders (HbA1C <7.5, or a decrease >1% on CSII, n=23) with nonresponders demonstrated no differences with respect to gender, socioeconomic status, weight standard deviation score, body mass index, initial HbA1C, frequency of hypoglycemia, or number of education visits before CSII.
Conclusion |
Continuous subcutaneous insulin infusion is effective in lowering HbA1C and the occurrence of severe nocturnal hypoglycemia without excessive weight gain in most children with type 1 diabetes. HbA1C response to CSII is poorer in preadolescents than in young children or teenagers.
Le texte complet de cet article est disponible en PDF.Abbreviations : CSII, HbA1C, SDS, TDD
Plan
 | S.M.W. is the recipient of a Clinical Associate Physician Award (3 MO 1 RR01700-20S2) from the NIH National Center for Research Resources. |
Vol 143 - N° 6
P. 796-801 - décembre 2003 Retour au numéro
Article précédent
- Acute respiratory disease with special reference to pathogenesis, classification, and diagnosis
- Blakeslee E. Noyes
- Complex regional pain syndrome after hepatitis B vaccine
- Wasil A Jastaniah, Simon Dobson, James G Lugsdin, Ross E Petty
Bienvenue sur EM-consulte, la référence des professionnels de santé.
L’accès au texte intégral de cet article nécessite un abonnement.
Déjà abonné à cette revue ?